Zurcher Kantonalbank (Zurich Cantonalbank) Concert Pharmaceuticals, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 01, 2022	SELL	$2.69 - $4.22 $12,107 - $18,994	-4,501 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.17 - $4.15 $91 - $120	29 Added 0.65%	4,501 $15,000
Q2 2021 Jul 30, 2021	BUY	$3.77 - $5.24 $1,315 - $1,828	349 Added 8.46%	4,472 $19,000
Q1 2021 May 03, 2021	BUY	$4.86 - $13.07 $20,037 - $53,887	4,123 New	4,123 $21,000
Q2 2019 Jul 30, 2019	SELL	$9.44 - $13.12 $13,357 - $18,564	-1,415 Closed	0 $0
Q1 2019 Apr 29, 2019	SELL	$12.07 - $17.54 $12,118 - $17,610	-1,004 Reduced 41.5%	1,415 $17,000
Q1 2018 May 03, 2018	SELL	$19.24 - $28.03 $62,510 - $91,069	-3,249 Reduced 57.32%	2,419 $55,000
Q4 2017 Jan 31, 2018	BUY	$13.96 - $29.05 $13,122 - $27,307	940 Added 19.88%	5,668 $147,000
Q3 2017 Nov 08, 2017	BUY	$13.91 - $15.31 $65,766 - $72,385	4,728	4,728 $70,000

Others Institutions Holding CNCE

# of Institutions

Shares Held

Call Options Held

Put Options Held

Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View Full List

About CONCERT PHARMACEUTICALS, INC.

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

More about CNCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account